1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Metropolis Healthcare Limited

Metropolis Healthcare Limited

METROPOLIS.NS
Metropolis Healthcare LimitedIN flagNational Stock Exchange of India
536.15
INR
-5.35
- -
111.16BMarket Cap
Metropolis Healthcare Limited
METROPOLIS.NS
(National Stock Exchange of India)

Recent

price

536.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
23.6
27.44
32.42
38.06
42.61
49
60.03
56.07
58.95
64.92
79.6
58.74
Revenue per Share
3.81
5.12
5.25
6.02
6.34
8.99
10.47
6.98
6.24
7.07
9.19
6.63
Basic EPS, GAAP
3.71
4.29
4.23
3.33
8.55
10.84
10.88
9.5
9.78
9.47
14.49
- -
Free Cash Flow per Basic Share
4.12
0.02
2.66
3.33
2
2.01
2
2
1
- -
1
- -
Dividend per Share
10.13
12.42
16.87
15.44
19.01
25.61
33.83
38.7
43.84
50.8
2.01
2
Book Value per Share
12.8
12.44
16.83
15.93
20.25
28.64
3.53
7.87
12.6
12.1
16.13
16.1
Tangible Book Value per Share
201
199
199
200
201
204
205
205
205
205
207
207
Basic Weighted Avg Shares
4,755
5,447
6,436
7,601
8,558
9,978
12,283
11,482
12,077
13,312
16,458
12,167
Sales/Revenue/Turnover
23.71
25.46
25.77
24.59
20.72
24.7
23.51
18.19
16.84
14.6
16.23
15.72
Operating Margin (%)
166
172
190
201
393
459
632
892
945
1,087
1,337
1,013
Depreciation Expense
768
1,017
1,042
1,201
1,273
1,831
2,142
1,429
1,278
1,450
1,900
1,373
Net Income, GAAP
35.73
32.93
31.67
33.74
24.41
24.96
26.82
23.52
26.47
23.76
26.23
26.5
Effective Tax Rate (%)
16.15
18.66
16.2
15.81
14.88
18.35
17.44
12.44
10.58
10.89
11.55
11.29
Profit Margin (%)
1,344
1,333
2,097
1,802
2,276
4,045
916
378
700
516
1,346
1,346
Working Capital
5
4
2
- -
458
789
2,413
1,541
1,191
1,121
1,383
1,383
LT Debt
2,939
3,442
4,291
4,200
5,252
7,081
8,882
9,907
10,993
13,346
15,246
15,246
Total Equity
- -
28.66
29.81
29.63
28.1
27.84
20.46
12.64
11.72
10.47
11.82
8.43
Return on Invested Capital (%)
- -
39.13
31.52
34.55
34.31
34.77
26.71
15.26
13.31
13.51
26.98
19.59
Return on Capital (%)
- -
45.12
35.86
37.36
36.9
40.55
35.29
19.24
15.12
14.95
35.08
25.36
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
936
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
1,383
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
207
- -
207
Market Capitalization
104,920
99,669
89,885

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
- -
- -
4,686
Cash, Cash Equivalents & STI
- -
- -
2,156
Accounts Receivable, Net
- -
- -
1,703
Inventories
- -
- -
455
Total Current Liabilities
- -
- -
3,340
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
936
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.31%
16.72%
14.23%
Free Cash Flow
22.13%
8.48%
54.28%
Net Income, GAAP
11.76%
3.53%
31.08%
Sales/Revenue/Turnover
13.56%
11.13%
23.64%
Total Cash Common Dividend
- -
- -
1.14%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,771
3,085
2,911
3,310
12,077
2025
3,134
3,498
3,228
3,453
13,312
2026
3,861
- -
4,059
4,247
16,458

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.4
1.73
1.32
- -
6.24
2025
1.85
2.27
1.53
1.42
7.07
2026
2.18
- -
2
2.46
9.19

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
1
Similar Companies
Illumina, Inc. (ILU.DE)
DermTech, Inc. (DMTKQ)
OpGen, Inc. (OPGN)
Medpace Holdings, Inc. (MEDP)
Suraksha Diagnostic Limited (SURAKSHA.BO)
Olink Holding AB (publ) (OLK)
Business
Metropolis Healthcare Limited Metropolis Healthcare Limited (METROPOLIS.NS) operates as a leading provider of diagnostic pathology and laboratory services in India and select international markets. Founded in 1980 and headquartered in Mumbai, Maharashtra, the company maintains a central reference laboratory in Mumbai alongside a network exceeding 170 advanced clinical labs, over 2,000 patient touchpoints, and collection centers spanning India, Africa (including Ghana, Kenya, Zambia, Uganda), South Asia (Sri Lanka, Mauritius), and the Middle East (UAE). It delivers a comprehensive portfolio of over 4,000 clinical laboratory tests and profiles across routine pathology (biochemistry, immunology, hematology, urine analysis, microbiology), advanced diagnostics (molecular, genetic, cytogenetic testing), semi-specialty and super-specialty domains (oncology, neurology, gynecology, nephrology), imaging services, wellness solutions (pre-employment check-ups, employee health plans, executive health packages, TruHealth preventive screenings), hospital laboratory management and outsourcing for multi-specialty facilities, and clinical trial support services including specimen logistics, analysis, data management, and long-term storage for contract research organizations and pharmaceutical manufacturers; all supported by NABL- and CAP-accredited labs, home sample collection, pediatric expertise, and digital reporting platforms. Geographically, Metropolis Healthcare Limited focuses on urban and Tier II/III markets in India while expanding internationally through established subsidiaries and partnerships, serving individual patients, hospitals, corporates, and physicians with science-led, high-accuracy diagnostics. In recent developments within the last 1-2 years, the company has aggressively pursued its "String of Pearls" acquisition strategy with four key deals to bolster geographic footprint and specialty capabilities: the April 2025 acquisition of Dehradun-based Dr. Ahuja’s Pathology and Imaging Centre for ₹35 crore to deepen North India presence; the March 2025 purchase of Scientific Pathology in Agra, Uttar Pradesh, for ₹55-83 crore, elevating North revenue share from 8% to 13-18% by FY26; the August 2025 buyout of Core Diagnostics in Delhi-NCR for ₹247 crore to enhance oncology expertise; and the September 2025 integration of Kolhapur’s Ambika Pathology Laboratory to strengthen Western Maharashtra operations; these moves, funded primarily through internal accruals, complement ongoing investments in genomics, AI-driven wellness, high-value testing, and a new oncology center of excellence while reporting 23% Q1FY26 revenue growth to ₹386 crore.